Table 3.
Outcomes and characteristics for people with CF diagnosed with SARS-CoV-2 before 13th June 2020, who have had an organ transplant (N = 32).
|
Hospitalisation |
Supplemental O2 |
ICU |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Total non-missing | No | Yes | Total non-missing | No | Yes | Total non-missing | No | Yes | |
| N = 27 | N = 7 | N = 20 | N = 23 | N = 11 | N = 12 | N = 28 | N = 21 | N = 7 | |
| Female; n (%1) | 9 | 4 (44) | 5 (56) | 8 | 4 (50) | 4 (50) | 11 | 11 (100) | 0 (0) |
| Male; n (%1) | 18 | 3 (17) | 15 (83) | 15 | 7 (47) | 8 (53) | 17 | 10 (59) | 7 (41) |
| Age; median (range) | 38 (9–50) | 38 (9–50) | 38 (15–48) | 39 (9–50) | 40 (15–50) | 38 (9–47) | 38 (9–50) | 38 (9–50) | 38 (27–47) |
| Age; n (%1) | |||||||||
| <18 | 2 | 1 (50) | 1 (50) | 2 | 1 (50) | 1 (50) | 2 | 2 (100) | 0 (0) |
| 18–39 | 14 | 3 (21) | 11 (79) | 10 | 4 (40) | 6 (60) | 14 | 10 (71) | 4 (29) |
| ≥40 | 11 | 3 (27) | 8 (73) | 11 | 6 (55) | 5 (45) | 12 | 9 (75) | 3 (25) |
| Genotype; n (%1) | |||||||||
| Homozygous F508del | 16 | 4 (25) | 12 (75) | 13 | 8 (62) | 5 (38) | 16 | 13 (81) | 3 (19) |
| Heterozygous F508del | 8 | 2 (25) | 6 (75) | 7 | 2 (29) | 5 (71) | 9 | 6 (67) | 3 (33) |
| Other | 2 | 0 (0) | 2 (100) | 2 | 1 (50) | 1 (50) | 2 | 1 (50) | 1 (50) |
| CFRD2; n (%1) | |||||||||
| No | 7 | 2 (29) | 5 (71) | 7 | 5 (71) | 2 (29) | 7 | 6 (86) | 1 (14) |
| Yes | 19 | 4 (21) | 15 (79) | 16 | 6 (38) | 10 (63) | 17 | 11 (65) | 6 (35) |
| Pseudomonas2; n (%1) | |||||||||
| No | 9 | 1 (11) | 8 (89) | 9 | 4 (44) | 5 (56) | 12 | 8 (67) | 4 (33) |
| Yes | 14 | 4 (29) | 10 (71) | 13 | 7 (54) | 6 (46) | 15 | 13 (87) | 2 (13) |
| Best FEV1; median (range) | 79.5 (19–114) | 78 (50–99) | 81 (19–114) | 81 (49–114) | 85 (50–99) | 75.5 (49–114) | 80.5 (49–114) | 81 (49–114) | 70 (50–91) |
| Best FEV12; n (%1) | |||||||||
| <40 | 1 | 0 (0) | 1 (100) | 0 | 0 (0) | 0 (0) | 0 | 0 (0) | 0 (0) |
| 40–70 | 7 | 1 (14) | 6 (86) | 7 | 2 (29) | 5 (71) | 8 | 5 (63) | 3 (38) |
| >70 | 12 | 4 (33) | 8 (67) | 12 | 7 (58) | 5 (42) | 16 | 14 (88) | 2 (13) |
| BMI; median (range) | 21 (16–29) | 21 (19–25) | 21 (16–29) | 21 (16–29) | 20 (16–25) | 22 (18–29) | 21 (16–29) | 21 (16–29) | 21 (16–24) |
1
Row proportions are calculated from the total non-missing in each outcome.
2
Where the values in a descriptive category do not add up to the overall column total (CFRD, Pseudomonas, Best FEV1) this indicates incomplete data in the given descriptive.